Rubric Capital Management (New York)’s Ovid Therapeutics OVID Stock Holding History

Rubric Capital Management (New York)’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-478,533	Closed	-$158K	–	79
2025 Q2	$158K	Sell	478,533 -4,837,436	-91%	-$1.46M	﹤0.01%	66
2025 Q1	$1.66M	Hold	5,315,969	–	–	0.03%	63
2024 Q4	$4.96M	Hold	5,315,969	–	–	0.06%	64
2024 Q3	$6.27M	Hold	5,315,969	–	–	0.1%	56
2024 Q2	$4.09M	Hold	5,315,969	–	–	0.11%	63
2024 Q1	$16.2M	Hold	5,315,969	–	–	0.48%	50
2023 Q4	$17.1M	Sell	5,315,969 -129,941	-2%	-$444K	0.36%	41
2023 Q3	$20.9M	Hold	5,445,910	–	–	0.78%	34
2023 Q2	$17.9M	Sell	5,445,910 -1,555,214	-22%	-$5.28M	0.76%	38
2023 Q1	$18.1M	Buy	7,001,124 +173,059	+3%	+$410K	0.47%	45
2022 Q4	$12.7M	Buy	6,828,065 +2,311,765	+51%	+$3.94M	0.55%	49
2022 Q3	$8.31M	Buy	4,516,300 +1,633,594	+57%	+$3.42M	0.42%	52
2022 Q2	$6.2M	Buy	+2,882,706	New	+$6.97M	0.33%	55

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Rubric Capital Management (New York)'s OVID Position: Q3 2025 in Review

Rubric Capital Management (New York) sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 478,533 shares — an estimated $158K sold.

Rubric Capital Management (New York) first reported a position in OVID in Q2 2022 and held it in 13 quarters. The position peaked at $20.9M in Q3 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

Rubric Capital Management (New York) reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
Rubric Capital Management (New York) sold 478,533 Ovid Therapeutics shares in Q3 2025, an estimated $158K.
Rubric Capital Management (New York) first reported a position in Ovid Therapeutics in Q2 2022 and held it in 13 quarters.
Rubric Capital Management (New York)'s Ovid Therapeutics position peaked at $20.9M in Q3 2023.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2025, filed 14 Nov 2025.